SkyCell

PharmaLifeScience News

...

Startup Glycomine raises $115M to push rare disease drug deeper into testing
The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in glycosylation.
READ MORE
...

Health department layoffs may be illegal, experts say
HHS bypassed normal procedures as it laid off thousands of employees, according to sources. One union has already filed an internal complaint, while at least two law firms are exploring suits.
READ MORE
...

Irish pharmaceutical exports to US soar amid tariff concerns
Irish medical and pharmaceutical exports to the US have seen a surge, with a year-on-year increase above 450% in February 2025.
READ MORE

Pharma companies issue demands to stay in EU ahead of expected US tariffs as Irish economy braces itself

Joint Swedish response to the EU’s new life science strategy

Trump order eases Medicare price negotiation for small molecule drugs

J&J expecting $400m hit from tariffs in 2025

Tánaiste says Ireland and EU ‘preparing for the worst’ amid trade talks with US

FDA to phase out animal testing with AI and lab-based models

Moderna authorised to upscale development of mRNA vaccines in UK

UK Biobank responds to fears over Chinese access to NHS data

Orexo and Abera Bioscience announce positive data

ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59

WHO member states agree on treaty to fight future pandemics

ProQR appoints new CFO and CMO to drive clinical-stage growth

Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

European Commission Alzheimer’s drug approval marks advancement for EU patients

Boehringer and Cue Biopharma to develop autoimmune therapies

AAX Biotech aims to enhance growth with two new appointments

Norgine on a growth charge again with Theravia takeover deal

Roche’s Columvi combo gains EC approval for DLBCL

Novartis commits $23bn to US manufacturing amid tariff threats

EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s

Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data
Ellab